A review of the treatment options for Huntington's disease

被引:34
作者
Bonelli, RM [1 ]
Hofmann, P [1 ]
机构
[1] Graz Univ, Psychiat Clin, A-8036 Graz, Austria
关键词
aggression; apathy; chorea; dystonia; depression; Huntington's disease; psychosis; treatment;
D O I
10.1517/eoph.5.4.767.30178
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Huntington's disease (HD) is an autosomal dominant, inherited, neuropsychiatric disease which gives rise to progressive motor, cognitive and behavioural symptoms. Its core pathology involves degeneration of the basal ganglia, in particular, the caudate and putamen, and is caused by a single autosomal gene coding for a mutated form of the protein, huntingtin. At the present time, the only treatment options available in HD are symptomatic. There are several substances available today for the treatment of chorea. Other neurological symptoms, such as dystonia, can be treated, but treatment is associated with a high risk of adverse events. Psychiatric symptoms, on the other hand, are often amenable to treatment and relief of these symptoms may provide significant improvement in quality of life.
引用
收藏
页码:767 / 776
页数:10
相关论文
共 137 条
[1]   Cognitive correlates of obsessive and compulsive symptoms in Huntington's disease [J].
Anderson, KE ;
Louis, ED ;
Stern, Y ;
Marder, KS .
AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (05) :799-801
[2]   THE RELATIONSHIP BETWEEN TRINUCLEOTIDE (CAG) REPEAT LENGTH AND CLINICAL-FEATURES OF HUNTINGTONS-DISEASE [J].
ANDREW, SE ;
GOLDBERG, YP ;
KREMER, B ;
TELENIUS, H ;
THEILMANN, J ;
ADAM, S ;
STARR, E ;
SQUITIERI, F ;
LIN, BY ;
KALCHMAN, MA ;
GRAHAM, RK ;
HAYDEN, MR .
NATURE GENETICS, 1993, 4 (04) :398-403
[3]  
Arena R, 1980, Adv Biochem Psychopharmacol, V24, P573
[4]   TETRABENAZINE AND MOVEMENT-DISORDERS [J].
ASHER, SW ;
AMINOFF, MJ .
NEUROLOGY, 1981, 31 (08) :1051-1054
[5]   SERUM HALOPERIDOL CONCENTRATION AND CHOREIFORM MOVEMENTS IN HUNTINGTONS-DISEASE [J].
BARR, AN ;
FISCHER, JH ;
KOLLER, WC ;
SPUNT, AL ;
SINGHAL, A .
NEUROLOGY, 1988, 38 (01) :84-88
[6]   Huntingtin aggregation and toxicity in Huntington's disease [J].
Bates, G .
LANCET, 2003, 361 (9369) :1642-1644
[7]   Buspirone in the management of disruptive behaviors due to Huntington's disease and other neurological disorders [J].
Bhandary, AN ;
Masand, PS .
PSYCHOSOMATICS, 1997, 38 (04) :389-391
[8]   Successful multimodality treatment of severe behavioral disturbance in a patient with advanced Huntington's disease [J].
Blass, DM ;
Steinberg, M ;
Leroi, I ;
Lyketsos, CG .
AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (12) :1966-1972
[9]   Minocycline for Huntington's disease: An open label study [J].
Bonelli, RM ;
Heuberger, C ;
Reisecker, F .
NEUROLOGY, 2003, 60 (05) :883-884
[10]   Mirtazapine in suicidal Huntington's disease [J].
Bonelli, RM .
ANNALS OF PHARMACOTHERAPY, 2003, 37 (03) :452-452